deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02340156

Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

Phase II Study of Combined Temozolomide and Targeted P53 Gene Therapy (SGT-53) for Treatment of Patients With Recurrent Glioblastoma

Sponsor: SynerGene Therapeutics, Inc.

Conditions RECURRENT GLIOBLASTOMA
Interventions SGT-53 Temozolomide
Updated 13 times since 2017 Last updated: Feb 11, 2021 Started: Dec 31, 2014 Primary completion: Nov 30, 2018 Completion: Nov 30, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

This PHASE2 trial investigates RECURRENT GLIOBLASTOMA and is currently terminated or withdrawn. SynerGene Therapeutics, Inc. leads this study, which shows 13 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshot~Sep 2019 – ~Apr 2020 · 7 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Dec 2021 · 8 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 8 earlier versions

  1. Apr 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Jan 2021 — Apr 2021 [monthly]

    Terminated PHASE2

  3. Apr 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  4. Sep 2019 — Apr 2020 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  5. Jun 2018 — Sep 2019 [monthly]

    Recruiting PHASE2

  6. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  7. Feb 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • SynerGene Therapeutics, Inc.
Data source: SynerGene Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations